ERBB2 and breast carcinoma: Though the tumors with the lowest ROR are the luminal A subtype, with little sensitivity to chemotherapy, a large proportion of patients with basal-like breast cancer were assigned intermediate ROR scores and saw a large benefit from chemotherapy and most of the chemotherapy-insensitive Her2-enriched tumors were assigned high ROR scores.